Bronchobiliary fistula after ablation of hepatocellular carcinoma adjacent to the diaphragm: Case report and literature review

Zhi-mei Huang1, Meng-xuan Zuo1, Yang-kui Gu1, Chun-xiao Lai2, Qiu-xiang Pan1, Xiao-cheng Yi3, Tian-qi Zhang1 & Jin-hua Huang1

1 Department of Minimal invasive intervention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
2 Department of Gastroenterology, Huangpu People’s Hospital, Zhongshan, China
3 Department of Medical Oncology, TCM Hospital of Ruichang, Ruichang, China

Keywords
Ablation; bronchobiliary fistula; hepatocellular carcinoma.

*Correspondence
Jin-hua Huang, Department of Minimal invasive intervention, Sun Yat-sen University Cancer Center, 651, Dongfeng East Road, Guangzhou 510060, China.
Tel: +86-20-87343447
Fax: +86-20-87343447
Email: huangjinhua_sysucc@126.com

†Zhi-mei Huang and Meng-xuan Zuo contributed equally.

Received: 16 September 2019; Accepted: 19 February 2020.

doi: 10.1111/1759-7714.13380

Thoracic Cancer 11 (2020) 1233–1238

Abstract

Background: Bronchobiliary fistula is a rare, but life-threatening complication after ablation of hepatocellular carcinoma. Few cases of bronchobiliary fistula have been reported and the treatment is controversial.

Methods: From 2006 to 2019, a total of 11 patients were diagnosed with bronchobiliary fistula after ablation and received nonsurgical treatment.

Results: All 11 patients presented with cough and bilioptysis. There were only two patients in which MRI revealed an obvious fistulous tract connecting the pleural effusion and biliary lesions. Pleural effusion, liver abscess and hepatic biloma were found in other patients. Three patients died of uncontrolled bronchobiliary fistula.

Conclusions: Bronchobiliary fistula is a rare post-ablation complication but should be taken into consideration in clinical decisions. Minimally invasive interventional treatment is a relatively effective means of dealing with bronchobiliary fistula, but as for the more severe cases, greater clinical experience is required.

Introduction

Hepatocellular carcinoma (HCC), which originates from liver cells, is a common type of primary liver cancer and the second-most frequent cause of tumor-related mortality worldwide. Currently, ablation is commonly used as a powerful treatment for HCC. This minimally invasive and repeatable treatment has been shown to be similarly effective as surgical excision for the treatment of small liver cancers, and in recent years, some medical centers have begun to apply ablation to the treatment of large HCC.

HCC ablation is associated with a low incidence of complications which are mostly mild-to-moderate, with reported overall complication rates of 2.2–5.7% and related mortality rates of 0%–1.4%. Notably, microwave ablation (MWA) contributes to higher mortality and complication rates, compared to radiofrequency ablation (RF). Despite its minimally invasive and generally safe characteristics, ablation may also have a series of specific complications which should be considered when making clinical decisions, including hemorrhage, hepatic dysfunction, gastrointestinal injury, biliary tract injury, infection, pleural complications, bronchobiliary fistula, and vascular fistula.

Bronchobiliary fistula is a rare post-ablation complication involving the formation of an abnormal channel between the biliary system and bronchial tree. The clinical manifestations of this complication include a recurrent bilioptysis, fever, jaundice, and chest pain. Some patients with a chronic course may develop potentially debilitating and life-threatening conditions such as bronchiectasis, hepatic lung disease, and anemia. Relatively few
published reports have reported bronchobiliary fistula after liver cancer ablation, and the treatment of bronchobiliary fistula are unclear. In this study, we retrospectively summarize the diagnosis and treatment of bronchobiliary fistula after HCC ablation at our center and analyze the possible pathogenesis of, and therapy for, bronchobiliary fistula based on the literature in order to provide clinical guidance.

Methods

Patient data

This retrospective study was approved by the Ethics Committee of our hospital, and all patients provided their signed informed consent before treatment. From May 2006 to August 2019, 1232 patients underwent computed tomography (CT)-guided ablation of HCC at our medical center according to the Chinese primary liver cancer diagnostic and treatment practices (2017 edition).

There were 11 patients who suffered bronchobiliary fistula after ablation, with an average age of 51.5 years (range: 38–63 years), 10 of whom were male. Tumor lesions of five cases were located in hepatic segment seven and tumor lesions of six cases were located in hepatic segment eight. The average lesion diameter was 78.7 mm (range: 40–133 mm) and the average distance between the applicator and diaphragm was 3.6 mm (range: 2–5 mm). Microwave ablation was performed in 11 cases, and another two cases received radiofrequency ablation and cryoablation separately. Further details of the patients are summarized in Table 1.

Ablation procedure

Under CT guidance (Elscint, Haifa, Israel), 1–5 applicators were placed percutaneously at the distal edge or interior of the tumor, depending on the tumor size. A single applicator was applied to tumors with a smaller diameter (<3 cm), while multiple applicators placed at intervals of <3 cm were applied to larger tumors. At least 5 mm adjacent normal liver tissue was ablated around the tumor to ensure a tumor-free margin. If the lesion was near the diaphragm (distance ≤5 mm), the ablation was controlled to avoid direct damage to the diaphragmatic tissue. CT and CT/magnetic resonance imaging (MRI) were performed immediately postoperatively and after 3–6 months, respectively, to assess efficacy and complication.

Results

Characteristics of bronchobiliary fistula

In all 11 cases involving bronchobiliary fistula, the ablation for HCC was completed successfully, with no complication or secondary injury occurring during the operation. The patients developed bronchobiliary fistula-related symptoms at an average of 19.8 days (range: 2–58 days) after the procedure.

Diagnosis of bronchobiliary fistula principally relies on clinical symptoms and imaging. All 11 patients presented with cough and biliophtysis, which were accompanied with fever in four cases (Table 1). Imaging scans (CT or MRI) revealed that all patients had different amount of pleural effusion. There were 3/11 patients who developed liver abscess, while 4/11 patients suffered obvious hepatic biloma. However, an obvious fistulous tract connecting the pleural effusion and biliary lesions was revealed in only two patients on MRI imaging (Fig 1). Digital subtraction angiography (DSA)-guided percutaneous transhepatic cholangiography (PTC) with a pigtail catheter was performed in the seven patients with obvious hepatic lesion, and injected contrast material revealed the presence of liver cavity or biliary dilatation. The remaining four patients exhibited unapparent or mild biliary tract dilatation (Fig 2).

Escherichia coli and fecal Enterococcus strains were isolated from a culture of the drainage material in one case, and in one case fecal Enterococcus and Klebsiella pneumoniae strains were isolated. Gram-positive bacteria were found in two other febrile cases.

Treatment and outcome

A total of seven patients consented to external biliary drainage as the main treatment for bronchobiliary fistula, of whom four patients manifested liver abscesses and were diagnosed as infection, so the anti-infective treatments were applied simultaneously according to the pathological evidence. The symptoms of cough and fever immediately relieved in six patients after the initiation of drainage and anti-infective treatment, and imaging examinations were repeated after continuous biliary drainage for a few months, which revealed satisfactory recovery of the liver and lung parenchyma, with no lesion between the intrahepatic biliary tree and bronchial tree. However, the treatment was poorly effective in one patient, and the patient finally died during follow-up of an uncontrollable infection and liver failure due to inadequate bile drainage. Another five patients died of gastrointestinal bleeding or tumor progression.

Two patients presented with a small amount of pleural effusion were applied with supportive treatment under comprehensive consideration. After six months, the patients’ discomfort resolved, and repeated imaging examinations revealed that the thoracic and biliary lesions had healed. One patient subsequently died of tumor progression, whereas the other achieved stable disease control and remains alive during the last follow-up.

Although two patients had no significant biliary tract lesions, they complained of biliophtysis and presented with...
| No. | Gender | Age | Location | Maximum diameter of tumor | Distance between applicator and diaphragm | Type | Time to ablation (days) | Power/ cycle | Symptoms | Imaging features | Infection | Management | Efficacy | State | Cause of death |
|-----|--------|-----|----------|---------------------------|-------------------------------------------|------|------------------------|-------------|----------|------------------|-----------|------------|----------|-------|----------------|
| 1   | Male   | 45  | S7       | 97 mm                     | 3 mm                                      | MWA  | 12 minutes             | 65 W        | 7        | Bilioptysis       | No        | Thoracic drainage | Unimproved | Dead   | Related       |
| 2   | Male   | 57  | S7       | 50 mm                     | 5 mm                                      | MWA  | 12 minutes             | 65 W        | 30       | Fever, Bilioptysis | Escherichia coli and fecal enterococci | Anti-infection, Thoracic drainage | Improved | Dead   | Unrelated     |
| 3   | Male   | 63  | S8       | 40 mm                     | 3 mm                                      | RFA  | 8 minutes              | 140 W       | 14       | Bilioptysis       | No        | Biliary drainage  | Improved  | Dead   | Unrelated     |
| 4   | Male   | 58  | S8       | 126 mm                    | 5 mm                                      | MWA  | 12 minutes             | 65 W        | 30       | Bilioptysis       | No        | Biliary drainage  | Improved  | Dead   | Unrelated     |
| 5   | Male   | 39  | S8       | 40 mm                     | 5 mm                                      | MWA  | 10 minutes             | 70 W        | 8        | Bilioptysis       | No        | Biliary drainage  | Improved  | Dead   | Unrelated     |
| 6   | Male   | 38  | S7       | 133 mm                    | 3 mm                                      | MWA  | 10 minutes             | 65 W        | 15       | Bilioptysis       | No        | Supportive treatment | Improved | Dead   | Unrelated     |
| 7   | Male   | 47  | S7       | 70 mm                     | 2 mm                                      | MWA  | 8 minutes              | 60 W        | 14       | Bilioptysis       | No        | Supportive treatment | Improved | Alive  | -             |
| 8   | Male   | 62  | S8       | 80 mm                     | 3 mm                                      | MWA  | 10 minutes             | 60 W        | 2        | Fever, bilioptysis | Gram-positive bacteria | Anti-infection, Biliary drainage | Improved | Dead   | Unrelated     |
| 9   | Male   | 63  | S8       | 100 mm                    | 3 mm                                      | Cryoablation | 15 minutes | 2 cycles | 58       | Fever, bilioptysis | Gram-positive bacteria | Anti-infection, Biliary drainage | Unimproved | Dead   | Related       |
| 10  | Female | 46  | S8       | 30 mm                     | 3 mm                                      | MWA  | 8 minutes              | 50 W        | 2        | Fever, bilioptysis | Fecal enterococci and Klebsiella pneumoniae | Anti-infection, Thoracic drainage | Unimproved | Dead   | Related       |
| 11  | Male   | 49  | S7       | 48 mm                     | 4 mm                                      | MWA  | 10 minutes             | 60 W        | 20       | Bilioptysis       | No        | Biliary drainage  | Improved  | Alive  | -             |
a medium to large amount of pleural effusion. Therapeutic percutaneous drainage was performed. After three days, the clinical symptoms of one patient disappeared, and the drainage volume decreased to <5 mL per day. Repeated imaging studies revealed a significant reduction in pleural effusion compared with the previous examination, and the drainage tube was removed. However, the patient immediately developed a significant pleural effusion with bilioptysis one week later and finally died of massive hemoptysis. Another patient simultaneously suffered infection and finally died of uncontrolled infection.

**Discussion**

Any event that causes damage to the biliary tract, diaphragm, or bronchioles may contribute to a bronchobiliary fistula. This condition can be divided into congenital and acquired bronchobiliary fistula, the latter of which is mainly caused by
primary or metastatic tumors. In recent years, the popularization and widespread application of ablation for the treatment of liver cancer has led to a gradual increase in the reports of postoperative bronchobiliary fistula. This specific type of iatrogenic bronchobiliary fistula is complex, associated with greater social problems, and places a greater burden on patients and their doctors. Therefore, it is very important to correctly diagnose and properly treat a postoperative bronchobiliary fistula.

Pathologically, postoperative bronchobiliary fistula arises from a biliary tract lesion after ablation. These lesions arise via two pathological mechanisms: (i) mechanic obstruction of the biliary tract by a thermal injury during treatment, and (ii) formation of a liver abscess or biloma after hepatic ablation. In this study, three patients presented with obvious liver abscesses, whereas the others involved biloma or different degrees of biliary dilatation. These lesions can cause an increase in biliary or intracavitary pressure, which may drive bile or pus into the chest via the diaphragm due to negative pressure when combined with an injury of the diaphragm. The thermal injury during ablation is the most common type of diaphragmatic injury. All patients in this study who developed a bronchobiliary fistula had large liver tumors located near the diaphragm (the shortest distance was 2 mm). After ablation, CT/MRI revealed that, in all cases, the ablation borders reached the diaphragm and different degrees of pleural effusion had developed, indicating the thermal injury to the diaphragm during the ablation procedures and the subsequent formation of a bronchobiliary fistula. Several case reports have also described the formation of bronchobiliary fistulae after the ablation of large tumors located near the diaphragm. The fistulae had a multifactorial etiology, and infection-induced diaphragmatic injury can also contribute to formation of a bronchobiliary fistula. In this study, three patients presented with bacterial infections.

Bilioptysis, or a productive cough of bile-stained sputum, is the most common and characteristic clinical manifestation of a bronchobiliary fistula. This manifestation can be detected through a biochemical examination. Other symptoms may include fever, chest pain, and abdominal pain. Some patients with emergent conditions may even develop an acute and life-threatening lung or artery injury. All patients in this article presented with an expectoration of yellow, bile-tinged sputum, and some patients also presented with a febrile infection.

Bronchobiliary fistula is mainly diagnosed with a CT or MRI scan. In this study, MRI only revealed obvious fistula tracts in two patients. By contrast, it is difficult to detect this tract in most cases, which is usually diagnosed with a combination of clinical symptoms and some indirect signs, including pleural effusion, atelectasis, liver abscess (cyst), and intrahepatic bile duct dilatation. The invasive diagnostic tool PTC can be used under DSA guidance to visualize the entrance of contrast agents into the thoracic cavity or lung from an intrahepatic lesion. It also has a unique advantage that biliary or thoracic PTC drainage can be performed immediately.

Surgical and supportive therapy are generally applied for the treatment of bronchobiliary fistula, although the latter is only suitable for patients with mild symptoms. In our study, the fistula tract was not detectable and only accompanied by mild biliary dilatation in two patients, and these patients achieved relief with no recurrence after supportive treatment. However, supportive treatment does not effectively resolve the fistula in most patients, which often result in frequent relapse and eventual surgical intervention. Surgical treatments can be divided into open surgical and minimally invasive interventional treatments. The former includes conventional treatments for bronchobiliary fistula, including lobectomy, local hepatectomy, and diaphragmatic fistula repair. However, some patients are considered high-risk for surgery, and resurgery after ablation is contraindicated for many other patients. In this study, 73% of patients underwent percutaneous transhepatic biliary drainage under CT or DSA guidance and received anti-infective treatment while under full drainage. Only one patient died due to incomplete drainage, and the remaining cases resolved within six months, which is relatively effective and safe for patients with bronchobiliary fistula.

In conclusion, bronchobiliary fistulas are pathological communications between the biliary tract and the pleural space, which has a great effect on the treatment and outcome of HCC patients. Our study revealed that minimal invasive interventional treatment could be an effective and safety therapy for bronchobiliary fistula. However, when dealing with severe cases, more radical intervention may be necessary and further studies are required.

Acknowledgments
This study was supported by the National Science Foundation of China (Grant Number 81371652), 5010 Project of Clinical Research in Sun Yat-sen University (Grant Number 2016002), Science and Technology Program of Guangzhou, China (Grant Number 201704020134).

Disclosure
The authors report no conflicts of interest.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65 (2): 87–108. PMID: 25651787.
Bronchobiliary fistula after ablation

Z.-m. Huang et al.

2. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011; 98 (9): 1210–24. PMID: 21766289.

3. Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 (3): 321–8. PMID: 16495695.

4. Liu Y, Zheng Y, Li S, Li B, Zhang Y, Yuan Y. Percutaneous microwave ablation of larger hepatocellular carcinoma. Clin Radiol 2013; 68 (1): 21–6. PMID: 22766484.

5. Yin XY, Xie XY, Lu MD et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: Long-term outcome and prognostic factors. Cancer 2009; 115 (9): 1914–23. PMID: 19241423.

6. Ding J, Jing X, Liu J et al. Complications of thermal ablation of hepatic tumours: Comparison of radiofrequency and microwave ablative techniques. Clin Radiol 2013; 68 (6): 608–15. PMID: 23399463.

7. Nemcek AA. Complications of radiofrequency ablation of neoplasms. Semin Intervent Radiol 2006; 23 (2): 177–87. PMID: 21326761.

8. Livraghi T, Meloni F, Solliati I et al. Complications of microwave ablation for liver tumors: Results of a multicenter study. Cardiovasc Intervent Radiol 2012; 35 (4): 868–74. PMID: 21833809.

9. Zhang L, Wang N, Shen Q, Cheng W, Qian GJ. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. PLOS One 2013; 8 (10): e76119. PMID: 24146824.

10. Takaki H, Yamakado K, Nakatsuka A et al. Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions: Single-center experience. AJR Am J Roentgenol 2013; 200 (3): 658–64. PMID: 23436859.

11. Rhim H, Yoon KH, Lee JM et al. Major complications after radio-frequency thermal ablation of hepatic tumors: Spectrum of imaging findings. Radiographics 2003; 23 (1): 123–34 discussion 134–6. PMID: 12533647.

12. Koda M, Murawaki Y, Hirooka Y et al. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients. Hepatol Res 2012; 42 (11): 1058–64. PMID: 22583706.

13. Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: A systematic review. Eur Radiol 2011; 21 (12): 2584–96. PMID: 21858359.

14. Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: Treatment with percutaneous microwave ablation—Comlications among cohort of 1136 patients. Radiology 2009; 251 (3): 933–40. PMID: 19304921.

15. Liao GQ, Wang H, Zhu GY, Zhu KB, Lv FX, Tai S. Management of acquired bronchobiliary fistula: A systematic literature review of 68 cases published in 30 years. World J Gastroenterol 2011; 17 (33): 3842–9. PMID: 21987628.

16. Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2013; 141 (5): 861–76. PMID: 25158999.

17. Warren KW, Christophi C, Armendariz R et al. Surgical treatment of bronchobiliary fistulas. Surg Gynecol Obstet 1983; 157 (4): 351–6. PMID: 6623325.

18. Crnjac A, Pivec V, Ivanecz A. Thoracobiliary fistulas: Literature review and a case report of fistula closure with omentum majus. Radiol Oncol 2013; 47 (1): 77–85. PMID: 23450657.

19. Yoon DH, Shim JH, Lee WJ, Kim PN, Shin JH, Kim KM. Percutaneous management of a bronchobiliary fistula after radiofrequency ablation in a patient with hepatocellular carcinoma. Korean J Radiol 2009; 10 (4): 411–5. PMID: 19568472.

20. Pende V, Marchese M, Mutignani M et al. Endoscopic management of biliopleural fistula and biloma after percutaneous radiofrequency ablation of liver metastasis. Gastrointest Endosc 2007; 66 (3): 616–8. PMID: 17521647.

21. Zeng Z, Cai M, Huang W et al. Delayed bronchobiliary fistula following radiofrequency ablation in a patient with hepatocellular carcinoma: A case report and lesson regarding treatment. Oncol Lett 2016; 11 (5): 3213–7. PMID: 27123093.

22. Kim YS, Rhim H, Sung JH et al. Bronchobiliary fistula after radiofrequency thermal ablation of hepatic tumor. J Vasc Interv Radiol 2005; 16 (3): 407–10. PMID: 15758140.

23. Tran T, Hampel H, Qureshi WA, Shaib Y. Successful endoscopic management of bronchobiliary fistula due to radiofrequency ablation. Dig Dis Sci 2007; 52 (11): 3178–80. PMID: 17638080.

24. Chang YC, Lin YM. Bronchobiliary fistula after radiofrequency ablation for hepatocellular carcinoma successfully treated by double drainage. Respirol Case Rep 2018; 6 (9): e00376. PMID: 30386621.

25. Eryigit H, Oztas S, Urek S, Olgac G, Kurutepe M, Kutlu CA. Management of acquired bronchobiliary fistula: 3 case reports and a literature review. J Cardiothorac Surg 2007; 2: 52. PMID: 18053192.

26. Ong M, Moozar K, Cohen LB. Octreotide in bronchobiliary fistula management. Ann Thorac Surg 2004; 78 (4): 1512–3. PMID: 15464539.

27. Peker Y, Can MF, Genç O, Gozubuyuk A, Zeybek N, Tufan T. Appropriate approach to bronchobiliary fistulas: A case series with hydatid disease and algorithm of case-based management. Int Surg 2007; 92 (4): 239–46. PMID: 18050836.

28. Tocchi A, Mazzoni G, Miccini M et al. Treatment of hydatid bronchobiliary fistulas: 30 years of experience. Liver Int 2007; 27 (2): 209–14. PMID: 17311615.

29. Aydin U, Yazici P, Tekin F, Ozutemiz O, Coker A. Minimally invasive treatment of patients with bronchobiliary fistula: A case series. J Med Case Reports 2009; 3: 23. PMID: 19166600.